Centre caps trade margins on 137 cancer drugs, prices likely to fall by up to 70%

AI summary preview · read the full story at Mint

• The Centre capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, with revised prices effective 9 November.
• The National Pharmaceutical Pricing Authority notified the cap under Paragraph 19 of the DPCO, 2013, citing markups of up to 700%.